Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: XL184-210 A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naive Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer

 


XL184-210 A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naive Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer


Trial Focus

Prostate Cancer

Objective

         This clinical trial plans to learn more about what effects adding cabozantinib to abiraterone plus prednisone has on prostate cancer that no longer responds to hormonal drugs and has spread to the bones. Cabozantinib is an anti-cancer agent which is appr

IRB Protocol #

13-3004

Trial Status

Archived

Principle Investigator

THOMAS FLAIG

Sponsor

Exelixis

Contact

MICHAEL WACKER at (720)848-3427 or MICHAEL.WACKER@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period will determine eligibility. The treatment period may last as long as the patient is responding to the study treatment or is experiencing unacceptable side effects. A follow-up period will consist of clinic visits and phone calls. // Eligibility criteria include but are not limited to 18 years or older with an metastatic castration-resistant prostate cancer that has gotten worse after other treatments and the prostate cancer has spread to the bones. Eligibility criteria include but are not limited to 18 years or older with an metastatic castration-resistant prostate cancer that has gotten worse after other treatments and the prostate cancer has spread to the bones.